Qia.De
The company operates in the healthcare diagnostics industry, providing products and services related to medical research and biotechnology.
Business. The company operates in the healthcare diagnostics industry, providing products and services related to medical research and biotechnology.
Analyst recommendations
14 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics industry, providing products and services related to medical research and biotechnology.
The company maintains a strong liquidity position, with a current ratio of 3.9, indicating a robust ability to meet short-term obligations. However, the company has a net cash position that is negative after subtracting total debt, which could pose a liquidity risk in the medium term. The debt-to-equity ratio of 0.44 suggests a relatively conservative capital structure, with a balance between debt and equity financing.
Profitability metrics show a return on equity of 11.25% and a return on assets of 6.76%, which are key indicators of the company's efficiency in generating returns for shareholders and asset utilization. These figures are in line with the industry's preferred metrics, suggesting the company is performing at a level consistent with its peers.
The company's revenue is primarily derived from its operations in the healthcare diagnostics industry, with no specific geographic concentration disclosed. The lack of detailed segment or geographic breakdown limits the ability to assess potential risks from over-reliance on specific markets or product lines.
Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue forecasted for the current and next fiscal years. This stability is supported by consistent operating cash flow and a manageable capital expenditure profile.
The company faces a medium liquidity risk, primarily due to its net cash position being negative after subtracting total debt. While the dilution risk is currently low, any future capital raising activities could affect the ownership structure. The company has not disclosed any recent dilutive events, and the dilution potential remains minimal.
Recent events and filings do not indicate any major operational or financial disruptions. The company's financial health appears stable, with no significant red flags in the latest disclosures. Analysts have provided a range of price targets, with a mean of 44.82 USD and a median of 44.20 USD, reflecting a generally positive outlook.
- The company has a strong liquidity position with a current ratio of 3.9.
- The company's return on equity of 11.25% is in line with industry standards.
- The company maintains a conservative capital structure with a debt-to-equity ratio of 0.44.
- Analysts have a generally positive outlook, with a mean price target of 44.82 USD.
- The company's growth trajectory is expected to remain stable in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,50 |
| Revenue | —no estimate | —no estimate | 2,2B USD |
| Operating income | —no estimate | —no estimate | 613,4M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- QIA.DE Market data — financials · 2026-05-29
- Qiagen NV Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$34M
- Investment Managers · as of 2026-03-310,00 %$41M
- Institutional Investor · as of 2026-03-310,00 %$0M